Soft tissue sarcoma of the extremities

SUNY Downstate Medical Center Brooklyn Veterans Hospital Valery Dronsky, M.D.

Soft Tissue Sarcomas of the Extremities

Soft Tissue Sarcomas: Definition


- Sarcomas are malignant tumors that arise from skeletal and extraskeletal connective tissue, mesenchymal cells, including:
 - adipose tissue
 - bone
 - cartilage
 - smooth muscle
 - skeletal muscle

Soft Tissue Sarcomas: Statistics

- Soft tissue sarcomas are rare and unusual neoplasms
 - about 1% of adult human cancers
 - 15% of pediatric malignancies
- Most commonly occur in the extremities (50%)
 - Also common in the abdominal cavity/retroperitoneum, trunk/thoracic region, and head and neck


Cell of origin	Sarcoma type				
Adipocyte	Liposarcoma				
Fibrohistiocyte	Malignant fibrous histiocytoma				
Fibroblast	Fibrosarcoma				
Smooth muscle	Leiomyosarcoma				
Skeletal muscle	Rhabdomyosarcoma				
Vascular	Angiosarcoma, Kaposi's				
Synovial	Synovial sarcoma				
Melanocyte	Malignant melanoma				
Unknown	Ewing's sarcoma, Epithelioid sarcoma				


- Histopathology is determined by anatomic site
 - Common subtypes in the extremity are liposarcoma and malignant fibrous histiocytoma
 - In the retroperitoneal location liposarcoma and leiomyosarcoma are the most common histiotypes
 - In the visceral location, gastrointestinal stromal tumors are found almost exclusively




- Age as factor in histopathology
 - In childhood, embryonal rhabdomyosarcoma is most common
 - Synovial sarcoma is more likely to be seen in young adults (<35 years old)
 - An even distribution of liposarcoma and malignant fibrous histiocytoma as the predominant types in the older population


- The biologic behavior of sarcomas is extremely variable
- Histologic grade is a major prognostic determinant and is based on degree of mitosis, cellularity, presence of necrosis, differentiation, and stromal content







- Low-grade sarcomasbetter-differentiated, less cellular, tend to resemble the tissue of origin to some extent, cytologic abnormalities are less prominent, mitotic rate is low
- Grow slower, low risk of metastasis, a high risk of local recurrence after surgical removal







- High-grade sarcomashighly cellular, poorly differentiated mesenchymal cells with marked nuclear abnormality, high mitotic rate and anaplasia
- Grow rapidly, show extensive local invasion, metastasize early through bloodstream, usually fatal





- Can be further characterized by cellular appearance:
 - well differentiated
 - undifferentiated
 - myxoid
 - round cell
 - pleomorphic





Soft Tissue Sarcomas: Risk Factors

- Genetic Predisposition
 - Neurofibromatosis -von Recklinghausen's disease
 - Li-Fraumeni syndrome
 - Retinoblastoma
 - Gardner's syndrome (familial adenomatous polyposis)

¹ Barken D, Wright E, Nguyen D: Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 236:1100, 1987.

² Li FP, Fraumeni JF: Soft-tissue sarcomas, breast cancer, and other neoplasms: A familial syndrome? Ann Intern Med 71:747, 1969.

³ Sorensen SA, Mulvihill JJ, Nielsen A: Long-term follow-up of von Recklinghausen neurofibromatosis: Survival and malignant neoplasms. N Engl J Med 314:1010, 1986

Soft Tissue Sarcomas: Risk Factors

- Radiation Exposure 1,2
- Lymphedema
 - Postsurgical
 - Postirradiation
 - Parasitic infection (filariasis)
- Trauma
- Chemical
 - 2,3,7,8-Tetrachlorodibenzodioxin
 - Polyvinyl chloride
 - Hemachromatosis
 - Arsenic

¹ Brady MS, Gaynor JJ, Brennan MF: Radiation-associated sarcoma of bone and soft tissue. Arch Surg 127:1379, 1992.

² Brennan MF, Lewis JJ: Diagnosis and Management of Soft Tissue Sarcoma. London, Martin Dunitz, 2002.

Soft Tissue Sarcomas: Pathogenesis


Specific genetic alterations :

fusion genes due to reciprocal

translocations

specific point mutations

- Nonspecific genetic alterations :
 - genetic losses and gains
- The tumor suppressor genes:
 - p53 and RB1



- Extremity sarcomas usually present with as a painless mass
- However, pain is noted at presentation in up to 33% of patients
- Delay in diagnosis is common, with the most common differential diagnosis for extremity and trunk lesions being a hematoma or a "pulled" muscle

Physical examination

should include assessment of the size of the mass and its relationship to neurovascular and bony structures

Biopsy

Generally, in an adult, any soft tissue mass that is symptomatic or enlarging, any mass that is larger than 5 cm, or any new mass that persists beyond 4 weeks should be sampled


Lewis J, Brennan MF: Soft tissue sarcomas. Curr Probl Surg 33:817, 1996

- Usually incisional or core biopsy preferred
 - Extremity masses should be biopsied through a longitudinal incision
 - Entire biopsy tract can be excised at the time of definitive resection
- The incision should be centered over the mass in its most superficial location
 - No tissue flap should be raised
 - Meticulous hemostasis to prevent cellular dissemination by hematoma



- Tru-cut core needle biopsy
 - Has been advocated as the first step in diagnosis
 - Ease of performance
 - Low cost
 - Low complication rate
- Incisional biopsy may be reserved for cases in which the core needle biopsy is inconclusive
- Biopsy is indicated only if the actual treatment will be altered by a definitive diagnosis






Heslin MJ, Lewis JJ, Woodruff JM, Brennan MF: Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol 4:425, 1997.

- Excisional biopsy
 - Only for small (< 3 cm) cutaneous or subcutaneous tumors
- Fine-needle aspiration
 - Limited role in diagnosing extremity soft tissue tumors
 - May be of value in the documentation of recurrence.




- Imaging
 - MRI preferred
 - enhances the contrast between tumor and adjacent structures
 - provides excellent three-dimensional definition of fascial planes



¹ Varma DG: Optimal radiologic imaging of soft tissue sarcomas. Semin Surg Oncol 17:2, 1999.

² Panicek DM, Go SD, Healey JH, et al: Soft-tissue sarcoma involving bone or neurovascular structures: MR imaging prognostic factors. Radiology 205:871, 1997.

- Imaging: Relative value of MRI and CT
 - No statistically significant difference between CT and MR imaging in determining tumor involvement of muscle, bone, joints, or neurovascular structures
 - Combination of CT and MR images did not significantly improve accuracy



Panicek DM, Gatsonis C, Rosenthal DI, et al: CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology 202:237, 1997

Soft Tissue Sarcomas: Workup

- Evaluation for sites of potential metastasis:
 - Lymph node metastases occur in less than 3% of adult soft tissue sarcoma¹
 - For extremity lesions, the lung is the principal site for metastasis of high-grade lesions²
 - For visceral lesions, the liver is the principal site³
- Low-grade lesions are assumed to have a low <15% risk of subsequent metastasis</p>
- High-grade lesions have a high >50% risk of subsequent metastasis

³ DeMatteo RP, Lewis JJ, Leung D, et al: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 231:51, 2000.

¹ Fong Y, Coit DG, Woodruff JM, Brennan MF: Lymph node metastasis from soft tissue sarcoma in adults: Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 217:72, 1993.

² Gadd MA, Casper ES, Woodruff JM, et al: Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg 218:705, 1993.

Soft Tissue Sarcomas: Workup

- Low-grade extremity lesions require a chest radiograph
- High-grade lesions require a chest CT
- Visceral lesions should have the liver imaged as part of the initial abdominal CT or MRI

- Staging systems focus on:
 - Histologic grade of the tumor
 - Size of the primary tumor
 - Presence or absence of metastasis
- Staging systems:
 - apply to risk of metastasis
 - disease-specific survival
 - overall survival
 - almost exclusively confined to extremity lesions

¹ Brennan MF: Staging of soft tissue sarcomas. Ann Surg Oncol 6:8, 1999

² Greene F, Page D, Fleming I, Fritz A, et al (eds): AJCC Cancer Staging Manual, 6th ed. Heidelberg, Springer-Verlag, 2002.

AJCC Staging - Soft Tissue Sarcoma

Histopathologic Grade

GX Grade cannot be assessed.

G1 Well differentiated.

G2 Moderately differentiated.

G3 Poorly differentiated.

G4 Undifferentiated.

Primary Tumor

TX Primary Tumor cannot be assessed.

70 No evidence of primary tumor.

T1 Tumor 5 cm or less in greatest dimension.

T1a Superficial tumor.

T1b Deep tumor.

Tumor more than 5 cm in greatest dimension.

T2a Superficial tumor.

T2b Deep tumor.

Note: Superficial tumor is located exclusively above the superficial fascia without invasion of the fascia; deep tumor is located either exclusively beneath the superficial fascia, or superficial to the fascia with invasion of or through the fascia or superfacial and beneath the fascia. Retroperitoneal, mediastinal, and pelvic sarcomas are classified as deep tumors.

Regional Lymph Nodes

NX Regional lymph nodes cannot be assessed.

No regional lymph node metastasis.

N1 Regional lymph node metastasis.

Distant Metastasis

MX Distant metastasis cannot be assessed.

M0 No distant metastasis.

M1 Distant metastasis.

The above four components are combined into the following staging criteria.

~ .	^	
Stage	Grou	nına
Otago	O , 0 u	P'''9

_	. •				
Stage I					
	A (Low grade, small, superficial and deep)	G1-2	T1a-1b	N0	MO
	B (Low grade, large,	G1-2	T2a	N0	MO
Ctoro II	superficial)				
Stage II	A /Low grado Jargo	G1-2	T2b	N0	MO
	A (Low grade, large, deep)	G1-2	120	INU	IVIO
	B (High grade, small,	G3-4	T1a-1b	N0	MO
	superficial, deep)	00.4	то -	NO	1.40
	C (High grade, large, superficial)	G3-4	T2a	N0	MO
Stage III	Superficial)				
	(High grade, large,	G3-4	T2b	N0	MO
Ctoro IV	deep)				
Stage IV	(any metastasis)	Any G	Any T	N1	MO
	(arry riiotadiadia)	Any G	Any T	NO	M1
		•	•		

- Surgical excision:
 - Greatest hope for cure
 - Whenever possible, function- and limb-sparing procedures should be performed
 - As long as the entire tumor is removed, less radical procedures do not adversely affect local recurrence or outcome
 - Goal is complete removal of the tumor with negative margins and maximal preservation of function

Rosenberg SA, Tepper J, Glatstein E, et al: The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 196:305, 1982.

Excision

- 1 to 2 cm margins
- Amputation no longer standard of care
- Meticulous dissection can prevent injury to major neurovascular structures



Williard WC, Collin C, Casper ES, et al: The changing role of amputation for soft tissue sarcoma of the extremity in adults. Surg Gynecol Obstet 175:389, 1992.

- Wide excision alone adequate for:
 - Any size low-grade sarcoma
 - Subcutaneous or intramuscular high-grade sarcoma < 5 cm
- Otherwise adjuvant therapy is indicated



Yang JC, Chang AE, Baker AR, et al: Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16:197, 1998.

- Adjuvant radiation should be added to the surgical resection:
 - If the excision margin is close
 - If extramuscular involvement is present
 - If a local recurrence would result in the sacrifice of a major neurovascular bundle or amputation



Yang JC, Chang AE, Baker AR, et al: Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16:197, 1998.

- Adjuvant radiation
 - improves local control
 - brachytherapy for highgrade lesions
 - external-beam radiation therapy for large (>5 cm) high- or low-grade lesions



¹ Yang JC, Chang AE, Baker AR, et al: Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16:197, 1998.

² Pisters PW, Harrison LB, Leung DH, et al: Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 14:859, 1996.

- Adjuvant chemotherapy
 - depends on the histologic type of sarcoma; indicated for:
 - Ewing's sarcoma
 - rhabdomyosarcoma
 - High risk of microscopic metastasis at diagnosis and good response to chemotherpy



¹ Baldini EH, Demetri GD, Fletcher CD, et al: Adults with Ewing's sarcoma/primitive neuroectodermal tumor: Adverse effect of older age and primary extraosseous disease on outcome. Ann Surg 230:79, 1999.

² Esnaola NF, Rubin BP, Baldini EH, et al: Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg 234:215, 2001.

- Adjuvant chemotherapy
 - Controversial for other histologic subtypes
 - Has no measurable impact on overall survival
 - Small (10% to 15%) improvement in diseasefree survival



¹ Bramwell V, Rouesse J, Steward W, et al: Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma-reduced local recurrence but no improvement in survival: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 12:1137, 1994.

² Tierney JF, Stewart LA, Parmar MKB, et al: (Sarcoma Meta-analysis Collaboration): Adjuvant chemotherapy for localised resectable soft-tissue

- Incidence of distant metastasis significant
 - Billingsley, et al: Of 994 patients with primary extremity soft tissue sarcomas distant metastasis developed in 230 patients (23%)¹
 - Median survival after the development of metastasis was 11.6 months
 - Lungs first metastatic site in 73%



Billingsley KG, Lewis JJ, Leung DH, et al: Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 85:389, 1999.

- Predictors of survival:
 - Extent of metastatic disease
 - Length of the disease-free interval
 - Presence of a preceding local recurrence
 - Age



Billingsley KG, Lewis JJ, Leung DH, et al: Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 85:389, 1999.

- Local extremity recurrence
 - Presents as a nodular mass or series of nodules arising in the surgical scar
 - If isolated should undergo reresection
 - two thirds of these patients experience long-term survival benefit
 - Adjuvant radiation if feasible



¹ Singer S, Antman K, Corson JM, Eberlein TJ: Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch Surg 127:548, 1992.

² Brennan MF: The enigma of local recurrence. The Society of Surgical Oncology. Ann

- Resection of pulmonary metastases:
 - Primary tumors controlled or controllable
 - No extrathoracic disease
 - Medically fit for thoracotomy
 - Complete resection of all lung disease appears possible
- 20% to 30% 3-year survival rates after complete resection

¹ Billingsley KG, Burt ME, Jara E, et al: Pulmonary metastases from soft tissue sarcoma: Analysis of patterns of diseases and post-metastasis survival. Ann Surg 229:602, 1999.

- Role of chemotherapy
 - Unresectable pulmonary metastases
 - Extrapulmonary metastatic sarcoma in more than a single site
 - Uniformly poor prognosis
 - DTIC (doxorubicin,ifosfamide,dacarbasine) and MAID (mesna, ifosfamide, doxorubicin, dacarbasine) have a 47% response rate and a 10% complete response rate
- Palliative, not curative, therapy

Benjamin RS, Rouesse J, Bourgeois H, van Hoesel QG: Should patients with advanced sarcomas be treated with chemotherapy? Eur J Cancer 34:958, 1998.

- Long-term follow-up
 - 9% of patients who were disease free at the end of 5 years would have further recurrence of the primary extremity sarcoma

Lewis JJ, Leung D, Casper ES, et al: Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg 134:190, 1999

Conclusions

- Sarcomas of the extremity can be extremely variable in terms of their histologic make-up, their natural history, and their biological behavior
- Surgical resection is the mainstay of curative therapy
- Multimodal treatment and salvage therapy have improved outcomes in a subset of patients